Nanobiotix stock more than triples, after biotech enters final negotiations with 'major' drug maker on development of cancer treatment

The U.S.-listed shares of Nanobiotix S.A. blasted 221.7% higher on massive volume Friday, to pace all gainers trading on major U.S. exchanges, after the France-based biotechnology company said it entered into final contract negotiations for the commercialization of its cancer treatment. Trading volume exploded to 27.9 million shares, compared with the full-day volume over the past 30 days of about 3,200 shares. The company said the negotiations come after an agreement to a non-binding term sheet with a "major global pharmaceutical company" for development and commercialization of its lead nanotherapeutic candidate NBTXR3. Nanobiotix's NBTXR3 is an novel oncology product made up of "functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy." The stock has now gained 77.9% year to date, while the iShares Biotechnology exchange-traded fund (IBB) was little changed and the S&P 500 has gained 7.2%.

-Tomi Kilgore

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

05-05-23 1208ET

Copyright (c) 2023 Dow Jones & Company, Inc.